Linked Life Data

11796686

Source:http://linkedlifedata.com/resource/pubmed/id/11796686

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2002-1-17
pubmed:abstractText
Preterm infants are often treated with intravenous dopamine to increase mean arterial blood pressure (MAP). However, there are few data regarding cerebrovascular responses of developing animals to dopamine infusions. We studied eight near-term and eight preterm chronically catheterized unanesthetized fetal sheep. We measured cerebral blood flow and calculated cerebral vascular resistance (CVR) at baseline and during dopamine infusion at 2.5, 7.5, 25, and 75 microg x kg(-1) x min(-1). In preterm fetuses, MAP increased only at 75 microg x kg(-1) x min(-1) (25 +/- 5%), whereas in near-term fetuses MAP increased at 25 microg x kg(-1) x min(-1) (28 +/- 4%) and further at 75 microg x kg(-1) x min(-1) (51 +/- 3%). Dopamine infusion was associated with cerebral vasoconstriction in both groups. At 25 microg x kg(-1) x min(-1), CVR increased 77 +/- 51% in preterm fetuses and 41 +/- 11% in near-term fetuses, and at 75 microg x kg(-1) x min(-1), CVR increased 80 +/- 33% in preterm fetuses and 83 +/- 21% in near-term fetuses. We tested these responses to dopamine in 11 additional near-term fetuses under alpha-adrenergic blockade (phenoxybenzamine, n = 5) and under dopaminergic D(1)-receptor blockade (SCH-23390, n = 6). Phenoxybenzamine completely blocked dopamine's pressor and cerebral vasoconstrictive effects, while D(1)-receptor blockade had no effect. Therefore, in unanesthetized developing fetuses, dopamine infusion is associated with cerebral vasoconstriction, which is likely an autoregulatory, alpha-adrenergic response to an increase in blood pressure.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
8750-7587
pubmed:author
pubmed:issnType
Print
pubmed:volume
92
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
717-24
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:11796686-Adrenergic alpha-Antagonists, pubmed-meshheading:11796686-Animals, pubmed-meshheading:11796686-Benzazepines, pubmed-meshheading:11796686-Blood Pressure, pubmed-meshheading:11796686-Cerebrovascular Circulation, pubmed-meshheading:11796686-Dopamine, pubmed-meshheading:11796686-Dopamine Antagonists, pubmed-meshheading:11796686-Dose-Response Relationship, Drug, pubmed-meshheading:11796686-Embryonic and Fetal Development, pubmed-meshheading:11796686-Fetus, pubmed-meshheading:11796686-Gestational Age, pubmed-meshheading:11796686-Injections, Intravenous, pubmed-meshheading:11796686-Phenoxybenzamine, pubmed-meshheading:11796686-Receptors, Dopamine D1, pubmed-meshheading:11796686-Sheep, pubmed-meshheading:11796686-Vasoconstriction, pubmed-meshheading:11796686-Vasoconstrictor Agents
pubmed:year
2002
pubmed:articleTitle
Cerebrovascular effects of intravenous dopamine infusions in fetal sheep.
pubmed:affiliation
Division of Neonatology, Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington 98195-6320, USA. cgleason@u.washington.edu
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.